Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $8.8333.

Several brokerages have recently weighed in on AQST. Zacks Research upgraded shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Citigroup reissued an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Finally, JMP Securities upped their target price on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 9th.

Aquestive Therapeutics Stock Performance

Shares of AQST stock opened at $3.16 on Friday. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $7.55. The stock has a 50 day simple moving average of $5.31 and a two-hundred day simple moving average of $5.21. The company has a market cap of $385.52 million, a P/E ratio of -4.45 and a beta of 1.66.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $12.81 million for the quarter, compared to the consensus estimate of $12.94 million. On average, research analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AQST. Victory Capital Management Inc. grew its stake in shares of Aquestive Therapeutics by 17.0% in the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock worth $72,000 after acquiring an additional 1,862 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Aquestive Therapeutics by 6.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after purchasing an additional 2,649 shares during the last quarter. BNP Paribas Financial Markets grew its position in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Aquestive Therapeutics by 16.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock worth $106,000 after purchasing an additional 4,557 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Aquestive Therapeutics by 31.1% during the 2nd quarter. Bank of Montreal Can now owns 20,052 shares of the company’s stock worth $66,000 after buying an additional 4,752 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.